PCSK9 and cardiovascular disorder: ODYSSEY-LONG TERM trial showed that the combination of PCSK9 inhibitors and statins could reduce the risk of MACEs by about 50% in patients with high-risk cardiovascular diseases, which provides a theoretical basis for the safety of clinical application of PCSK9 inhibitors.55 56 Based on this, we believe that the powerful lipid-lowering and potential anti-inflammation effects of PCSK9 inhibitors could promote the improvement of coronary microcirculation and cardiac function after PCI.